Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on RxSight RXST in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 3 | 0 | 0 | 0 |
| Last 30D | 2 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $65.6, a high estimate of $75.00, and a low estimate of $54.00. Observing a 19.03% increase, the current average has risen from the previous average price target of $55.11.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive RxSight. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steven Lichtman | Oppenheimer | Raises | Outperform | $72.00 | $61.00 |
| David Saxon | Needham | Raises | Buy | $75.00 | $64.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $72.00 | $61.00 |
| Thomas Stephan | Stifel | Raises | Buy | $68.00 | $64.00 |
| David Saxon | Needham | Maintains | Buy | $64.00 | - |
| Thomas Stephan | Stifel | Raises | Buy | $64.00 | $54.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $62.00 | $40.00 |
| Steven Lichtman | Oppenheimer | Raises | Outperform | $61.00 | $54.00 |
| David Saxon | Needham | Raises | Buy | $64.00 | $53.00 |
| Thomas Stephan | Stifel | Raises | Buy | $54.00 | $45.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to RxSight. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RxSight compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of RxSight's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into RxSight's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on RxSight analyst ratings.
Unveiling the Story Behind RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Breaking Down RxSight's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining RxSight's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 77.65% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: RxSight's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -32.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RxSight's ROE excels beyond industry benchmarks, reaching -5.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): RxSight's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.04%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: RxSight's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
